Fast Track Validation Programme

The EP PerMed Fast Track Programme offers targeted support to accelerate the validation and adoption of innovative personalised medicine solutions. The programme helps early-stage innovations progress by at least one Technology Readiness Level through dedicated validation studies carried out together with specialised European validation centres.

Closed Frast Track Calls

  • Fast Track Validation Programme 2026

    The EP PerMed Fast Track Programme 2026 offers targeted support to accelerate the validation and adoption of innovative personalised medicine solutions. The programme helps early-stage innovations progress by at least one Technology Readiness Level through dedicated validation studies carried out together with specialised European validation centres.

    Read more: Fast Track Validation Programme 2026
  • Fast Track Validation Programme 2025

    Eight outstanding projects were selected for the EP PerMed Fast Track Validation Programme, an initiative designed to accelerate the development, validation, and adoption of innovative personalised medicine (PM) solutions across Europe.

    Read more: Fast Track Validation Programme 2025

The EP PerMed Fast Track Programme has been established to address a critical bottleneck in the development of personalised medicine solutions: the validation phase. Personalised medicine is a highly innovative and technology-driven field with significant potential to improve patient outcomes and optimise healthcare delivery. However, turning promising innovations into market-ready solutions requires rigorous validation to ensure they effectively meet the needs and expectations of end-users, including clinicians and patients. Validation plays a central role in achieving and sustaining product–market fit, which is a key factor for successful adoption and commercialisation. It involves a comprehensive assessment of whether a solution adequately addresses identified needs and challenges and is typically carried out in specialised validation centres that offer the necessary infrastructure and expertise. Despite the availability of such centres across Europe, many innovators face difficulties in identifying and accessing the most suitable resources, which can slow down the progress of their projects.

The programme supports start-ups, small teams, and researchers at a crucial stage of development, ensuring that promising innovations do not stall due to a lack of validation resources or guidance. It equips innovators with the tools, expertise, and knowledge needed to bring their solutions closer to clinical application and patient benefit. By providing a structured pathway for validation, the programme enables participants to generate critical evidence and receive valuable feedback within a condensed six-month timeframe. This accelerated process is designed to help projects advance by at least one Technology Readiness Level and strengthen their readiness for market entry and commercialisation. Each call under the programme has a total budget of 400,000 EUR and offers funding of up to 80,000 EUR per selected project. Through this six-month accelerated pathway, successful applicants are connected with European validation centres, where they can implement and refine their validation plans in a focused and efficient manner.